AmmPower Corp
VANCOUVER, BC / ACCESSWIRE / July 19, 2021 / AmmPower Corp. (CSE:AMMP)(OTCQB:AMMPF)(FSE:601A) (the "Company" or "AmmPower"), is pleased to announce the appointment of Dr. Zhenyu Zhang, Ph.D as Chief Technologist.
Dr Zhang is a graduate of the Colorado School of Mines, one of the few leading research universities in the ammonia energy field. There he specialized in the development of catalytic membrane reactors for efficient ammonia synthesis and decomposition. As Chief Technologist he will lead AmmPower's development of both novel ammonia producing catalyst technologies as well as hydrogen releasing ammonia dissociation or "cracking" technologies.
Dr. Gary Benninger, AmmPower CEO and Executive Chairman welcomed Dr. Zhang by saying, "I am very pleased to personally welcome Zhenyu to our AmmPower team where he will hold a key leadership position, guiding us in our quest to create a greener world."
Dr Zhang has published several scientific papers in this field. In a series of Dr. Zhang's publications presented at the ACS Sustainable Chemistry & Engineering journal and the American Institute of Chemical Engineers (AIChE) annual meetings, he proposed the design of a novel configuration for catalytic membrane reactors for simultaneous hydrogen production and purification from ammonia decomposition.
The success of this work also led to the launch of a research project, with a $2 million research award funded by the Department of Energy (DOE), where Dr. Zhang led the project in conceptualization, process design, data curation, and formal analysis. Dr. Zhang's pioneering studies have created a pathway for future ammonia production that is distributed, more energy-efficient, and powered by renewables.
Dr. Zhang's position at AmmPower received recommendation support from academic innovators and international industry experts, including professors from Colorado School of Mines, Clarkson University, State University of New York Buffalo, science specialists at Saudi Aramco, and a program manager at New Energy Nexus.
Mr. Bharti, AmmPower President states, "Dr. Zhang is truly a global leader in the green ammonia space. As Chief Technologist, Dr. Zhang will help lead our incredible team in the delivery of novel, economical, and scalable solutions in bringing green ammonia to our near-term customers around the world. AmmPower is incredibly fortunate to have someone as distinguished as Dr. Zhang join the company."
Dr. Zhang holds a B.S. in Chemical Engineering from Central South University (China), an M.S. in Computer Science from Georgia Institute of Technology, and a Ph.D. in Chemical Engineering from Colorado School of Mines.
On Behalf of the Board of Directors
Gary Benninger
Chief Executive Officer
About AmmPower
AmmPower is a resource exploration company with an increasing focus on clean energy. The Company is based in Vancouver, BC and owns the Whabouchi South lithium exploration property located in the James Bay/Eeyou Istche region of Quebec and holds an option over the Titan Property located in the Klotz Lake area in Northwestern Ontario. In addition, together with its partner, ORF Technologies Inc., based in Toronto, Canada, the Company is working on the development of a proprietary solution to produce green ammonia and green hydrogen, and is also investigating revolutionary catalyst methods to react Nitrogen and Hydrogen together with the aim of creating 100% clean, and cost effective green, turquoise, and blue ammonia.
Investor Relations
604-398-3379
invest@ammpower.com
Forward-Looking Statements
This news release includes forward-looking statements that are subject to risks and uncertainties, including with respect to the expected timing of its name and ticker symbol changes. All statements within, other than statements of historical fact, are to be considered forward-looking. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company's public filings under the Company's SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
The Canadian Securities Exchange (CSE) has not reviewed, approved or disapproved the contents of this press release.
SOURCE: AmmPower Corp
View source version on accesswire.com:
https://www.accesswire.com/655985/AmmPower-Corp-is-pleased-to-announce-the-appointment-of-Dr-Zhenyu-Zhang-PhD-as-Chief-Technologist
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Cambridge Isotope Laboratories, Inc. Unveils ISOAPI-D - a New Standard in Deuterated Reagents for Pharmaceutical Innovation - at CPhI Frankfurt 202527.10.2025 14:00:00 CET | Press release
With ISOAPI-D, CIL offers pharmaceutical partners a secure, global supply of deuterated reagents - manufactured to the highest quality standards for faster, more efficient API development. TEWKSBURY, MASSACHUSETTS / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope chemistry, announces the launch of ISOAPI-D™, a unified brand of deuterated intermediates for API synthesis. The new ISOAPI-D brand will be launched at CPhI Frankfurt, where CIL welcomes industry professionals to stand #2.0G2 from October 28-30.ISOAPI-D ISOAPI-D Power of Deuterium: Smarter, Stronger Therapeutics "ISOAPI-D reagents are designed to support the development of next-generation active pharmaceutical ingredients (APIs) by leveraging the unique benefits of deuterium incorporation," said Cliff Caldwell, CEO of CIL. "With ISOAPI-D, our customers gain access to a trusted and secure supply chain, ensuring they have consistent, reliable access to the materi
Cambridge Isotope Laboratories, Inc. and Chemtatva Chiral Solutions Pvt. Ltd. to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India27.10.2025 13:45:00 CET | Press release
Strategic Partnership to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad's Genome Valley, Enhancing Global Production and Supply of Isotopically Enriched Chemical Solutions for Pharmaceutical and Electronics Industries TEWKSBURY, MA AND HYDERABAD, INDIA / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), and Chemtatva Chiral Solutions, Pvt. Ltd. (CCS), a leading provider of chiral and specialty chemical solutions, announce the execution of a signed Memorandum of Understanding to establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India. This initiative marks a milestone in the expansion of CIL's global footprint and further enhances capabilities in the development and production of deuterated reagents and other isotopically enriched products. This partnership will enhance global supply chain strength and real-time support for customers in Asia and enable multi-site production for global customers focused on business continui
Sauce Labs and Deque Systems Partner to Deliver Comprehensive Accessibility Testing at Scale24.10.2025 07:00:00 CEST | Press release
SAN FRANCISCO, CA / ACCESS Newswire / October 24, 2025 / Sauce Labs Inc., a leading provider of continuous testing solutions, and Deque Systems, Inc., a trusted leader in digital accessibility, today announced a strategic partnership to help companies ensure compliance with accessibility regulations and deliver accessible digital experiences across all devices and platforms. The collaboration combines Sauce Labs' extensive real-device coverage and scalable cloud infrastructure with Deque's unparalleled accessibility expertise. This partnership is a renewed commitment, building on a long-standing relationship between the two companies. By doubling down on their joint offering, Sauce Labs and Deque are providing a comprehensive solution for accessibility testing at scale. The partnership addresses the growing need for businesses to meet digital accessibility standards, especially with the upcoming European Accessibility Act (EAA), which became law on June 28, 2025. The EAA requires produ
Florence Connects 65,000+ Study Sites and 600+ Sponsors Worldwide - Unleashing the Next Era of Clinical Trial Intelligence23.10.2025 14:00:00 CEST | Press release
With the industry's largest network of sites, Florence sets a new benchmark for AI-enabled study startup, workflow automation, and operational risk management. ATLANTA, GA / ACCESS Newswire / October 23, 2025 / Florence Healthcare reinforced its position as the global leader in clinical trial operations with a major milestone: Florence Trial Operations Platform now connects 65,000 study sites spanning more than 600 sponsors across 90+ countries, forming the industry's largest network. Recognized as the #1 clinical trial technology for six consecutive years, Florence continues to set the standard for startup speed, workflow automation, and operational risk management across sponsor study portfolios. "Florence was built to bring sponsors and sites into a shared operational space," said Ryan Jones, CEO of Florence Healthcare. "First, we fully digitized startup to eliminate manual bottlenecks and paper workflows. Now, we're using AI to enhance speed and augment intelligence across 65,000 s
U.S. Polo Assn. Wins Gold and Silver Stevie Awards at the 2025 International Business Awards in Lisbon, Portugal23.10.2025 13:00:00 CEST | Press release
LISBON, PT AND WEST PALM BEACH, FL / ACCESS Newswire / October 23, 2025 / USPA Global today announced that U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has been awarded two prestigious Stevie® Awards from the 22nd Annual International Business Awards® (IBA).U.S. Polo Assn. Wins Two Stevie® Awards U.S. Polo Assn. was celebrated during an elegant gala event at the Corinthia Hotel in Lisbon, Portugal, on Friday, October 10, attended by leadership from USPA Global and the brand's strategic partners in the region. The global event hosted over 350 guests from more than 30 nations, including many of the world's top companies and Stevie winners, including Coca-Cola, Starbucks, Lenovo, Kendra Scott, IBM, and Turkish Airlines. The brand's winning entries included a Gold Stevie Award for 'Achievement in International Expansion' and a Silver Stevie Award in 'Celebration Event' for the 2024 Paris Games Polo Challenge campaign. The multi-billion-dollar, sp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
